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initiating IFX treatment between 7/1/2007 and 7/31/2011. Index date was the date of 
first IFX claim; 6 months pre- and 12 months post-index were required. Medication 
Possession Ratio (MPR) was calculated as [total days on IFX therapy based on infu-
sion dates and assumed duration of action/360 days]; at least two infusions were 
required. MPR thresholds of ≥ 80% and ≥ 60% were used to classify adherent patients. 
All-cause and CD-related costs per patient per month by place of service were calcu-
lated, adjusted to 2011 dollars. Results: A total of 173 patients were identified, 156 
of which had at least 2 infusions. Mean age was 47.9 years, 59.5% were female, and 
53.8% had Commercial coverage. Across the MPR thresholds, adherent patients had 
significantly higher all-cause physician office visit costs, and lower other outpatient 
visit, emergency department and hospitalization costs than non-adherent patients. 
CD-related costs showed similar trends for physician office visit, other outpatient 
visit and hospitalization costs. IBD-drug related costs were significantly higher in 
the adherent group; all-cause pharmacy costs were similar between those adherent 
and non-adherent. Total CD-related costs were higher among adherent patients (80% 
MPR, $2532.5(±1439.8) vs. $1949.3(±1395.1), p-value 0.0002), while total all-cause costs 
were similar between groups (80% MPR, $3236.(±1717.0) vs. $3084.8(±1859.4), p-value 
0.2564). ConClusions: Although adherent patients have higher physician office 
visit and IBD-drug related costs, hospitalization cost was significantly higher for 
non-adherent patients resulting in similar total all-cause costs for both the adher-
ent and non-adherent groups. Further research should quantify the clinical value 
of greater adherence against this backdrop of cost neutrality.
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objeCtives: There is little research regarding the cost effectiveness of ostomy 
pouching systems. There is also limited evidence regarding the patient preferences 
of these devices. The aim was to investigate the patient preferences of individual 
characteristics of ostomy pouching systems. The aim was also to rank these char-
acteristics based on patient preferences. Methods: All ostomy pouching systems, 
within the Swedish reimbursement system, were documented and their individual 
characteristics (i.e. properties of the filter, base plate and pouch material etc) iden-
tified both for closed-end and open-end bags. The significance of the identified 
characteristics was validated by a group of stoma nurses and experts. A pilot test 
of the interview guide for the focus group interviews were also held, resulting in 
small changes of the guide. Stoma nurses at nine different clinics in in different 
areas of Sweden consecutively asked stoma patients to participate. Patients were 
included if they gave oral and written consent, had a colostomy or ileostomy for at 
least one year. The patients were requested, together with the other participants 
in the focus group, to rank these individual characteristics of the ostomy pouching 
systems. Results: In total, 53 patients were included in the nine focus groups 
performed (one from each of the nine participating clinics). The top ranked patient 
preferences regarding closed-end bags were that the filter should reduce smell and 
should not leak but also that the base plate has good adhesive properties as well 
as being skin friendly. The top ranked patient preferences regarding open-end bags 
were also that the filter should reduce smell and should not leak. The bag should 
be easy to empty but also that the base plate has good adhesive properties as well 
as being skin friendly. ConClusions: The top-ranked patient preferences were 
mainly characteristics regarding the filter and base plate.
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objeCtives: Canadian inflammatory bowel disease (IBD) patients treated with 
infliximab are predominantly managed through a nationwide case management 
system, named BioAdvance, providing access to care, educational tools, supplies and 
assistance programs. The aim of this study was to identify underlying factors that 
were associated with positive changes in health outcomes. Methods: Between 
August 1 and September 30, 2012, a web-based survey was provided to patients cur-
rently receiving infliximab therapy within BioAdvance. The cross-sectional survey 
included items on demographic, disease characteristics, services usage and prefer-
ence, and perception of health and work absenteeism. Patients were categorized 
according to health trajectories: declined in health (decliners), no improvement 
(non-changers), moderate improvement and large improvements (strong increas-
ers). Multivariable multinomial logistic regression was used to determine which 
factors were associated with different health trajectories. Results: 918 of 1160 
respondents were IBD patients reporting health status. Patients were treated for 
Crohn’s disease [CD] (66.1%), Ulcerative Colitis [UC] (26.6%) or 2 or more conditions 
(7.3%). Strong increasers were most prevalent (53.2%) and decliners least preva-
lent (3.7%). Strong increasers were more likely to use educational tools than non-
changers (adjusted odds ratio [aOR]: 1.65; 95% confidence interval [CI]: 1.03-2.64), to 
be treated for UC than CD (aOR: 2.05; 95%CI: 1.16-3.64) and to perceive BioAdvance 
as important (aOR: 2.52; 95%CI: 1.56-4.09). There were no factors distinguishing 
decliners from non-changers. Younger patients were less likely to miss workdays, as 
were French speaking patients and, consistent health trajectories, patients treated 
for UC (aOR: 0.68; 95%CI: 0.47-0.97). Patients were more likely to have missed work-
days prior to joining BioAdvance (aOR: 2.76; 95%CI: 2.02-3.76). ConClusions: IBD 
patients receiving infliximab within the nationwide case management system 
report a positive impact on health status and absenteeism. Our study identified 
factors about the program that aremore impactful (educational tools) and patient 
factors that could improve program outcomes.
impairment, and numerically greater decreases in absenteeism, versus placebo at 
all study weeks. Differences relative to placebo in change from baseline to Week 
26 were -0.3% for absenteeism (NS), -5.9% for presenteeism, -7.5% for overall work 
productivity loss, and -6.7% for daily activity impairment (all 3 P< 0.05). Assuming a 
40-hour work week, linaclotide reduced overall work productivity loss by 3.0 hours/
week at Week 26. This translates to 156 hours/year which, based on average US 
wages, corresponds to an avoided overall work loss of $93 per patient/week or $4,861 
per patient/year. ConClusions: Compared with placebo, once-daily linaclotide 
treatment significantly reduced overall work productivity loss and activity impair-
ment among IBS-C patients, with improvements seen at all measured time points 
over 26 weeks of treatment.
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objeCtives: To examine the association between adherence and site of care 
among individuals with inflammatory bowel disease (IBD) treated with inflixi-
mab. Methods: Adult patients with new claim(s) for infliximab (no claims for at 
least 360 days) between January 1, 2006 to December 31, 2009 and ≥ 2 IBD diagno-
ses of Crohn’s disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC; ICD-9-CM: 
556.XX) were identified from Thomas Reuters Marketscan® Databases. Patients were 
required to be continuously enrolled for 12 months before and after infliximab 
initiation (index date). Patients with evidence of another biologic or rheumatoid 
arthritis (ICD-9-CM: 714.XX) were excluded. Being adherent was defined as having 
an infliximab medication possession ratio (MPR) of ≥ 80%. MPR was calculated as 
the sum of unduplicated days of therapy based on infusion dates and duration of 
action from prescribing information, divided by 360 days. Site of care was obtained 
from the first infliximab infusion claim. Sites were divided into three settings: office, 
outpatient hospital and “other” (e.g., home, ER). Odds of being adherent versus 
non-adherent were compared for these settings in a logistic model controlling for 
patient characteristics and resource use variables. Results: 1646 IBD patients were 
identified; 57.4% CD and 42.6% UC. The mean (SD) age was 44.4 (15.6) years and 51.7% 
were male. On index, 1,052 (63.9%) patients had a site of care for office on their first 
infliximab infusion claim, 510 (31.0%) had outpatient hospital, and 84 (5.1%) had 
“other”. Patients in the office setting had greater odds of being adherent relative 
to outpatient hospital (p< 0.0001; OR 2.5, 95% CI [1.9, 3.2]) and ‘other’ (p= 0.0039; 
OR 2.1, 95% CI [1.3, 3.4]). Outpatient hospital was not significantly different than 
the ‘other’ location (p= 0.5204). ConClusions: Findings suggest that having an 
office site of care is associated with increased infliximab adherence relative to the 
outpatient hospital setting.
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objeCtives: To describe adherence in Crohn’s disease (CD) patients receiving 
infliximab (IFX) by site-of-care (SOC). Methods: The Humana claims database 
was utilized to identify patients aged 18-89 with CD newly initiating IFX treatment 
between 7/1/2007 and 7/31/2011. Index date was the date of first IFX claim; 6 months 
pre- and 12 month post-index were required. Medication Possession Ratio (MPR) 
was calculated as [sum days’ supply of IFX based on infusion dates and assumed 
duration of action]/[sum days’ between first infusion and last days supply of last 
infusion]; therefore patients required ≥ 2 infusions. SOC types included physician 
office, outpatient hospital department, and ambulatory infusion centers. SOC was 
classified as ≥ 75% of infusions from one site; patients without a majority of infu-
sions from one site were classified as mixed-site. Results: A total of 173 patients 
were identified; 156 had at least 2 infusions. Mean age was 47.9 years, 59.5% were 
female, and 53.8% had Commercial coverage. Hospital outpatient (48.0%) and physi-
cian office (36.4%) were the most common SOC for index dose; among those who 
reached the maintenance phase, this same trend was observed. Mean MPR was 
similar across SOC (range 0.8 to 0.9, p-value 0.4412). Further, the proportion of 
patients considered adherent (≥ 80% MPR) was 72.4% among patients with physi-
cian office as primary SOC. The proportion of patients with ≥ 80% MPR in the other 
site types were similar to that of physician office patients (61.3%, 71.4%, and 81.0% 
for hospital outpatient, ambulatory infusion centers, and mixed site, respectively; 
p-value= NS). ConClusions: IFX adherence rates among CD patients did not vary 
significantly across different sites of care. Research evaluating other factors, such 
as patients’ preferences and satisfaction, may be useful in further characterizing 
available sites of care and supporting optimal site of care selection.
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objeCtives: To describe health care costs among Crohn’s disease (CD) patients 
receiving infliximab (IFX) by different adherence thresholds. Methods: The 
Humana claims database was utilized to identify patients aged 18-89 with CD newly 
